GLIATECH, INC.

Basic Information

GLIATECH, INC.
23420 COMMERCE PARK RD
CLEVELAND, OH, 44122

Company Profile

n/a

Additional Details

Field Value
DUNS: n/a
Hubzone Owned: N
Socially and Economically Disadvantaged: N
Woman Owned: N
Number of Employees: n/a


  1. NOVEL GLYCINE TRANSPORTER INHIBITORS FOR SCHIZOPHRENIA

    Amount: $93,862.00

    The glutamate/glycine NMDA receptor has been implicated in a variety of central nervous system disorders and pathological conditions. In particular, NMDA receptor hypofunction may contribute significa ...

    SBIR Phase I 2002 Department of Health and Human Services
  2. N/A

    Amount: $750,000.00

    N/A

    SBIR Phase II 1999 Department of Health and Human Services
  3. Development of Novel Chiral Cyclic Histamine H3 Agonists

    Amount: $621,379.00

    The long-term objectives are to synthesize novel cyclic and heterocyclic histamine H3 receptor agonprodrugs thereof that have improved GI absorption and CNS penetration. These agents are being develot ...

    SBIR Phase II 1998 Department of Health and Human Services
  4. COMBINATORIAL CONSTRUCTION OF NOVEL IMIDAZOLE LIBRARIES

    Amount: $99,832.00

    N/A

    SBIR Phase I 1998 Department of Health and Human Services
  5. DEVELOPMENT OF DRUGS FOR SCHIZOPHRENIA AND DEMENTIA

    Amount: $97,517.00

    N/A

    SBIR Phase I 1998 Department of Health and Human Services
  6. ANTIPROPERDIN AGENTS AS NOVEL ANTIINFLAMMATORIES

    Amount: $97,516.00

    N/A

    SBIR Phase I 1998 Department of Health and Human Services
  7. Evaluation of a Novel H3 Antagonist, GT 2016, for Add

    Amount: $721,665.00

    The long-term objectives are to develop novel histamine H3 receptor antagonists to increase wakefuland enhance cognitive abilities. The specific aims of this grant are (1) to test a novel non- thiourf ...

    SBIR Phase II 1997 Department of Health and Human Services
  8. INHIBITION OF POSTOPERATIVE GYNECOLOGICAL ADHESIONS

    Amount: $99,076.00

    N/A

    SBIR Phase I 1997 Department of Health and Human Services
  9. MOLECULAR CHARACTERIZATION--HISTAMINE RECEPTOR SUBTYPES

    Amount: $99,535.00

    N/A

    SBIR Phase I 1997 Department of Health and Human Services
  10. Development of Novel Chiral Cyclic Histamine H3 Agonists

    Amount: $100,000.00

    The long-term objectives are to synthesize novel cyclic and heterocyclic histamine H3 receptor agonprodrugs thereof that have improved GI absorption and CNS penetration. These agents are being develot ...

    SBIR Phase I 1995 Department of Health and Human Services

Agency Micro-sites

US Flag An Official Website of the United States Government